| No. |
HIV-NAT Protocol No. |
International code |
Title |
| 1 |
HIV-NAT 006 |
Adult cohort |
A long-term post study follow-up for HIV-infected patients previously participate in HIV-NAT study protocols
|
| 2 |
HIV-NAT 015 |
Ped cohort |
Treatment outcome of children with HIV infection |
| 3 |
HIV-NAT 027 |
SQV |
Efficacy and safety of saquinavir based regimen in HIV-1 infected Thai patients who have chronic IDV associated nephrotoxicity
|
| 4 |
HIV-NAT 031 |
SQV/r polymorphism |
Study of Genetic Polymorphisms of CYP 3A and MDR-1 genes in Thai HIV-1 infected Patients on Saquinavir/Ritonavir |
| 5 |
HIV-NAT 032 |
HIV-HBV immunology |
Generation of HBV-specific T-cell immunity in individuals with HIV/HBV co-infection receiving HBV-active antiretroviral therapy
|
| 6 |
HIV-NAT 033 |
TB/HIV |
A 48 week, randomized, open-label, 2 arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after initiating rifampin containing antituberculous therapy
|
| 7 |
HIV-NAT 035 |
PREDICT Or CIPRA |
An open label, randomized study to compare antiretroviral therapy (ART) initiation when CD4+ is between15-24% to ART initiation when CD4+ falls below 15% in children with HIV infection and moderate immune suppression |
| 8 |
HIV-NAT 035.1 |
Neuro sub-study of PREDICT |
A neurodevelopment sub-study of PREDICT: The effect of immediate versus deferred antiretroviral initiation on neurodevelopment in children with HIV in Cambodia and Thailand |
| 9 |
HIV-NAT 036 |
Anti-HBc |
The efficacy of HBV vaccine response and prevalence of Occult HBV infection in isolated anti HBc between HIV infected and HIV un-infected Thai patients |
| 10 |
HIV-NAT 038 |
SQV+RTV |
Bio-equivalence study of generic GPO saquinavir and Norvir? versus Invirase? and Norvir? in Thai healthy volunteers
|
| 11 |
HIV-NAT 040 |
NCI |
Prevalence and risk factors of HIV-associated neurocognitive impairment and psychiatric comorbidities in HIV-1 infected Thai individuals with undetectable viral load in the HAART era. |
| 12 |
HIV-NAT 041 |
SQV/TDF |
Pharmacokinetic and efficacy of Saquinavir mesylate film coated tablet / ritonavir 1500/100 plus Tenofovir/emtricitabine 300/200 mg once daily in HIV pretreated patients : (Sub study of HIV-NAT006: A long-term follow-up study for HIV-infected patients participated in HIV-NAT study protocols.) |
| 13 |
HIV-NAT 042 |
BITE |
A Randomised, Double-blind, Controlled Study on the Effect of One Year Administration of a Nutritional Concept on Immunological Status in HIV-1 Positive Adults not on Antiretroviral Therapy |
| 14 |
HIV-NAT 043 |
SARA |
The Pharmacokinetics of SAquinavir (Invirase new tablet formulation) 1,000 mg + Ritonavir (Norvir) 100 mg q 12 h in HIV-NAT-infected pregnAnt women (SARA). |
| 15 |
HIV-NAT 044 |
(bPI) |
A Pilot study of the pharmacokinetics and safety of ritonavir-boosted indinavir 600/100mg bid combined with nucleoside analogue reverse transcriptase inhibitors in antiretroviral na?ve HIV/TB co-infected patients receiving rifampicin containing anti-tuberculosis therapy |
| 16 |
HIV-NAT 045 |
Kaletra low dose |
Pharmacokinetics and efficacy of low-or standard-dose of lopinavir/ritonavir (Kaletra?) in PI-na?ve HIV-1 infected children |
| 17 |
HIV-NAT 060 |
TMC125-C206 |
A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options |
| 18 |
HIV-NAT 062 |
TMC278-C204 |
A Phase IIb, randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naive HIV-1 infected subject |
| 19 |
HIV-NAT 063 |
TMC114-C214 |
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/RTV versus LPV/RTV in treatment-experienced HIV-1 infected subjects. |
| 20 |
HIV-NAT 064 |
VACCINE OR HVDDT-N01-AI-05395 AE |
A Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS – HIV – AE (DNA) Prime and rFPV – HIV – AE Boost HIV Vaccination Strategy |
| 21 |
HIV-NAT 065 |
ESPRIT |
A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2(Proleukin?) in Patients With HIV-1 Infection and CD4+ Cell Counts > 300/mm3 :Evaluation of Subcutaneous Proleukin? in a Randomized International Trial(ESPRIT) |
| 22 |
HIV-NAT 065.1 |
TOXIL-2 |
An open-label, randomized study comparing the uptake of rIL-2 in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT: Toxicity substudy of ESPRIT (TOXIL-2) |
| 23 |
HIV-NAT 066 |
PENTA 11 |
Treatment Interruption in Children with Chronic HIV-Infection: the TICCH Trial |
| 24 |
HIV-NAT 067 |
TMC114-C211:ARTIMIS |
A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ ritonavir in treatment-na?ve HIV-1 infected subjects |
| 25 |
HIV-NAT 068 |
STALWART:ESPRIT002 |
A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and CD4+ Cell Counts > 300/mm3 : Study of Aldesleukin with and without Antiretroviral Therapy (ESPRIT 002: STALWART) |
| 26 |
HIV-NAT 069 |
BI1100.1452 |
A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients who have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 Weeks of Nevirapine Therapy |
| 27 |
HIV-NAT 070 |
TMC125-C217 |
An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator-selected OBR in HIV-1 infected subjects who participated in a DUET trial (TMC125-C206 or TMC125-C216) |
| 28 |
HIV-NAT 072 |
The Altair Study |
A Randomised Open-Label Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens (Truvada, efavirenz, zidovudine, Atazanavir, ritonavir and abacavir) as Initial Therapy for HIV Infection |
| 29 |
HIV-NAT 072.1 |
The MRS sub-study of Altair |
THE MRS SUB STUDY: A Randomised Open-Label Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection |
| 30 |
HIV-NAT 076 |
Death Study |
10 Years Mortality and Disease Progression Analysis of HIV-infected Patients in HIV-NAT Long Term Cohort |
| 31 |
HIV-NAT 077 |
Mono PI |
Simplifying antiretroviral treatment in virally suppressed children by switching from dual boosted lopinavir/ritonavir/saquinavir to lopinavir/ritonavir monotherapy |
| 32 |
HIV-NAT 078 |
MET-THAI |
Motivation Enhancement Therapy for Health Risk Behaviors in HIV+ Thai Youth |
| 33 |
HIV-NAT 080 |
TApHOD |
The TREAT Asia Paediatric HIV Observational Database |
| 34 |
HIV-NAT 082 |
Adherence |
Predictors and outcome assessment of adherence to antiretroviral medications in Thailand, as a resource constrained setting in Asia |
| 35 |
HIV-NAT 083 |
RTV low dose |
Pharmacokinetics of low dose Ritonavir in Thai Patients on a Saquinavir 1500 mg based HAART Regimen |
| 36 |
HIV-NAT 084 |
BI:1182.71/POTENT |
A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista? (Darunavir, DRV/r) in three-class (NRTI, NNRTI, and PI) treatment-experienced patients with resistance to more than one PI. |
| 37 |
HIV-NAT 086 |
Single Vs Dual Boosted PI |
Comparing the efficacy and safety of single versus double ritonavir-boosted protease inhibitor (PI)-based antiretroviral therapy (ART) regimens for children failing non nucleoside reverse transcriptase inhibitor (NNRTI)-based treatment |
| 38 |
HIV-NAT010.1 |
Iron study |
Change in iron status in HIV-infected children with moderate immune suppression |
| 39 |
HIV-NAT064.1 |
Social Impact |
Evaluate Social impact of preventive HIV vaccine clinical trial in participation |
| 40 |
HIV-NAT064.2 |
Circumstances pertaining to participant in Vaccine Trial |
Qualitative study on circumstances pertaining to participation in a Preventive HIV Vaccine Clinical Trial (Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS-HIV-AE DNA Prime and rFPV-HIV-AE Boost HIV Vaccination) |
| 41 |
HIV-NAT079 |
HIVSTAR |
The HIV Second-line Therapy AntiRetroviral study in patients who failed NNRTI-based regimens |
| 42 |
HIV-NAT079-01 |
HIVSTAR-Neurology compartment |
Effect of HIV and antiretroviral therapy on central nerves system in subjects treated with Lopinavir/ritonavir monotherapy VS 2NRTI plus lopinavir/ritonavir: substudy of HIVSTAR ;Neurology compartment |
| 43 |
HIV-NAT079-02 |
HIVSTAR-Genital compartment |
Effect of HIV and antiretroviral therapy on genital compartment in subjects treated with Lopinavir/ritonavir monotherapy VS 2NRTI plus lopinavir/ritonavir: substudy of HIVSTAR |
| 44 |
HIV-NAT087 |
MK-0518 |
Early Access of MK-0518 in Combination with an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients with Limited to No Treatment Options |
| 45 |
HIV-NAT088 |
AVX-301 |
A phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V/I mutation in reverse transcriptase |
| 46 |
HIV-NAT089 |
TMC114-TiDP31-C229 |
A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early triatment-experienced HIV-1 infected subjects |
| 47 |
HIV-NAT092 |
longitudinal HIV/HBV Cohort |
Liver disease and HIV/HBV coinfection in the era of HAART:A prospective longitudinal cohort, Thailand |
| 48 |
HIV-NAT093 |
Lopinavir/ritonavir in Pregnant women |
The Pharmacokinetics and Safety of Generic Lopinavir/ritonavir (200/50 mg tablets) 400/100 mg q12h in Thai HIV-infected Pregnant Women |
| 49 |
HIV-NAT095 |
TDM |
Therapeutic Drug Monitoring of generic lopinavir/ritonavir tablets 200/50 mg in the Thai HIV-infected Patient |
| 50 |
HIV-NAT096 |
NV20911 |
A phase I/II study of Invirase boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old. |
